Valuation Abbott Laboratories Sao Paulo
Stocks
ABTT34
BRABTTBDR007
Medical Equipment, Supplies & Distribution
|
Market Closed -
Sao Paulo
03:53:50 08/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 41.40 BRL | +1.57% |
|
-3.02% | -27.82% |
| 10-07 | Abbott Introduces Ensure Max Protein 3-In-1 Muscle Support Protein Powder | CI |
| 10-07 | Barclays Initiates Coverage on Abbott Laboratories With Overweight Rating, $120 Price Target | MT |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 170,841 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -21.58% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 194,780 | 191,798 | 188,108 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -12.37% | -1.53% | -1.92% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 28.9x | 22.4x | 19.6x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.57x | 3.42x | 3.24x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -3.54x | 0.8x | 1.4x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.4x | 3.13x | 2.93x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.88x | 3.52x | 3.23x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15x | 13.3x | 11.8x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 16.6x | 14.7x | 13.1x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 25.8x | 21.5x | 19.6x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.87% | 4.65% | 5.1% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.57 | 2.741 | 2.898 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.6% | 2.78% | 2.94% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.416 | 4.402 | 5.024 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 75.2% | 62.3% | 57.7% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,201 | 54,527 | 58,253 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,982 | 14,468 | 15,892 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,720 | 13,022 | 14,320 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,212 | 7,894 | 8,780 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 98.73 | 98.73 | 98.73 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 26/1/22 | 25/1/23 | 24/1/24 | 22/1/25 | 22/1/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 28.9x | 3.88x | 15x | 2.6% | 171B | ||
| 18.29x | 3.35x | 11.99x | 3.29% | 109B | ||
| 21.44x | 4.22x | 14.73x | 1.3% | 106B | ||
| 25.95x | 2.55x | 10.25x | 2.76% | 75.43B | ||
| 17.37x | 0.2x | 12.71x | 0.75% | 60.54B | ||
| 30.77x | 7.6x | 19.7x | 1.3% | 53.16B | ||
| 34.72x | 3.37x | 11.54x | 2.18% | 49.07B | ||
| 34.31x | 8.53x | 24x | -.--% | 39.92B | ||
| 33.87x | 5.94x | 18.63x | -.--% | 31.81B | ||
| Average | 27.29x | 4.40x | 15.39x | 1.58% | 77.31B | |
| Weighted average by Cap. | 25.87x | 3.99x | 14.57x | 1.97% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABTT34 Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
















